<DOC>
	<DOCNO>NCT00239642</DOCNO>
	<brief_summary>Comparison three potential iron sucrose maintenance regimen pediatric chronic kidney disease ( CKD ) patient</brief_summary>
	<brief_title>Safety Efficacy Iron Sucrose Children</brief_title>
	<detailed_description>Randomized , control , open label trial pediatric CKD patient stable erythropoietin ( EPO ) therapy . Patients follow 12 week assess safety ( incidence adverse event ) efficacy ( clinical success )</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Ferric oxide , saccharated</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>Patients 2 21 year age Patients stable hemodialysis ( HD ) peritoneal dialysis ( PD ) regimen 3 month ≥ 3 month Nondialysis dependent ( NDD ) patient glomerular filtration rate ( GFR ) &lt; 60 Hemoglobin ( Hgb ) ≥ 11g/dL ≤ 13.5g/dL Ferritin ≤ 800 ng/mL Transferrin saturation ( TSAT ) ≥ 20 % ≤ 50 % Received stable erythropoietin ( EPO ) regimen ≥ 8 week prior qualify screen visit Known hypersensitivity iron sucrose Severe diseased liver , cardiovascular system , hemopoietic system Serious infection require hospitalization Significant blood loss within last 3 month Bleeding disorder Pregnancy / Lactation Actively treat asthma Hemoglobinopathy Receiving myelosuppressive drug</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Iron</keyword>
	<keyword>Anemia</keyword>
	<keyword>CKD</keyword>
</DOC>